References
- Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–263.
- Cristofaro P, Opal SM. Role of toll-like receptors in infection and immunity: clinical implications. Drugs. 2006;66:15–29.
- Marshall JC. Endotoxin in the pathogenesis of sepsis. Contrib Nephrol. 2010;167:1–13.
- Cohen J. The detection and interpretation of endotoxaemia. Intensive Care Med. 2000;26:51–56.
- Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280–287.
- Bottiroli M, Monti G, Pinciroli R, et al. Prevalence and clinical significance of early high endotoxin activity in septic shock: an observational study. J Crit Care. 2017;41:124–129.
- Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. Jama. 2009;301:2445–2452.
- Cutuli SL, Artigas A, Fumagalli R, et al. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6:77.
- Lee CT, Tu YK, Yeh YC, et al. Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients. J Crit Care. 2018;43:202–206.
- Chang T, Tu YK, Lee CT, et al. Effects of Polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017;45:858–864.
- Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–984.
- Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted Polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. Jama. 2018;320:1455–1463.
- Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44:2205–2212.
- Singer M, Deutschman CS, Seymour CW, et al. Third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016;315:801–810.
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
- Leone S, Damiani G, Pezone I, et al. New antimicrobial options for the management of complicated intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 2019;38:819–827.